Earnings call
Aurobindo Pharma Q4 FY25 earnings call: Aurobindo Pharma does not expect a major impact from the tariff announcement likely in July ‘25, but says it needs to wait for the announcement
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company does not expect a major impact from the tariff announcement likely in July ‘25, but says it needs to wait for the announcement. Net capital was US$ 90 million in Q4 FY25 and around US$ 322 million in FY25, including capacity enhancement projects, new plant expansions and others. The company reported FY25 revenue of Rs. 31,724 crores and EBITDA of Rs. 6,605 crores, with a margin of 20.8%. Cash flows improved significantly on the backdrop of an improved working capital position, leading to a net cash surplus of US$ 42 million versus net debt of US$ 84 million as on December 31, 2024; its net cash position after investment stood at US$ 42 million, compared with a net debt position of US$ 84 million.
The numbers management gave
Results
- The company reported FY25 revenue of Rs. 31,724 crores and EBITDA of Rs. 6,605 crores, with a margin of 20.8%.
Show source
For FY25, our revenues stood at Rs. 31,724 crores and EBITDA at Rs. 6,605 crores, marking a comfortable margin of 20.8%.
- The company reported Q4 FY25 revenue of Rs. 8,382 crores and EBITDA of Rs. 1,792 crores, with a margin of 21.4%.
Show source
For Q4 FY25, our revenues stood at Rs. 8,382 crores and EBITDA of Rs. 1,792 crores, with a good margin of 21.4%.
- Profitability improved significantly, backed by softening raw material prices, favourable product and business mix, and improved operating efficiencies in the fourth quarter and year ended March 31, 2025.
Show source
The profitability of the company as well improved significantly, backed by softening of raw material prices, favourable product and business mix, and improved operating efficiencies.
- EBITDA margin was up from 20.1% of last year in the fourth quarter and year ended March 31, 2025.
Show source
This is reflected in the EBITDA margin which is up from 20.1% of last year.
- Reported numbers were achieved despite one-time recurring expenses on account of fuel and power purchase coal adjustments relating to the Andhra Pradesh government electricity board, inventory-related provisions and corporate development costs in the fourth quarter and year ended March 31, 2025.
Show source
These numbers have been achieved despite one-time recurring expenses on account of fuel and power purchase coal adjustments relating to the Andhra Pradesh government electricity board, inventory-related provisions and corporate development costs .
- PLI facilities contributed a negative of Rs. 30 crores plus at Aurobindo Pharma Limited's EBITDA level in the fourth quarter and year ended March 31, 2025.
Show source
In addition to these, PLI facilities contributed a negative of Rs. 30 crores plus at the EBITDA level.
Show 38 more statements
Results
- The accumulated impact of the one-time expenses and PLI facilities was a negative of Rs. 105 crores plus for Aurobindo Pharma Limited in the fourth quarter and year ended March 31, 2025.
Show source
The accumulated impact of the above factors was a negative of Rs. 105 crores plus.
- Other income was Rs. 123 crores in Q4 FY25, compared to Rs. 143 crores in Q3 FY25 and Rs. 153 crores in Q4 FY24.
Show source
The contribution of other income vis -à-vis Q3 FY25 and Q4 FY24 were lower at Rs. 123 crores compared to Rs. 143 crores and Rs. 153 crores respectively.
- Q4 FY25 revenue grew by 11% year-on-year and 5% quarter-on-quarter.
Show source
Now let me take you through the other details of the results for the 4th Quarter of FY25 and full year FY25 declared by the company : For Q4, revenues grown by 11% year -on-year and 5% quarter-on-quarter.
- Gross contribution reached its highest-ever absolute level of Rs. 4,954 crores in Q4 FY25.
Show source
The gross contribution stood at highest ever absolute levels of Rs. 4,954.
- EBITDA before forex and other income grew by 6% year-on-year and 10% quarter-on-quarter to Rs. 1,792 crores in Q4 FY25.
Show source
Consequently, the EBITDA before forex and other income grew by 6% year- on-year and by 10% quarter-on-quarter to Rs. 1,792 crores.
- Net profit increased by 7% quarter-on-quarter to Rs. 903 crores in Q4 FY25.
Show source
Net profit increased by 7% quarter-on-quarter to Rs. 903 crores.
- FY25 revenue grew by 9% year-on-year, supported by growth across businesses.
Show source
For the full year FY25, revenue grew by 9% year-on-year, supported by growth across businesses.
- Gross contribution reached its highest-ever absolute level of Rs. 18,697 crores in FY25, with a margin of 58.9%, an improvement of 240 bps.
Show source
Gross contribution also reached the highest ever absolute levels of Rs. 18,697 crores, reflecting a margin of 58.9%, and that's an improvement of 240 bps.
- Formulation business grew by 12% year-on-year to Rs. 7,313 crores and contributed around 87% of total revenue in Q4 FY25; revenues were mainly supported by growth across the US and Europe businesses.
Show source
Formulation business: Formulation business witnessed a growth of 12% year-on-year to Rs. 7,313 crores and contributed around 87% of the total revenue.
- Formulation business grew by 12% year-on-year to Rs. 27,388 crores and contributed around 86% of total revenue in FY25, driven by growth across the businesses.
Show source
For the full year FY25, formulation business witnessed a growth of 12% year-on-year to Rs. 27,388 crores and contributed around 86% of the total revenue.
- API businesses contributed around 13% and revenue improved by 5% year-on-year to Rs. 1,069 crores in Q4 FY25.
Show source
3 Aurobindo Pharma Limited 27 May 2025 API businesses: For the quarter, API businesses contributed around 13% and revenue improved by 5% year-on-year to Rs. 1,069 crores.
- API business contributed around 14% and clocked revenue of Rs. 4,323 crores in FY25; external business registered growth of 2%.
Show source
For the full year, API business contributed around 14% and clocked a revenue of Rs. 4,323 crores, which is being the external business, registering a growth of 2%.
- API business growth was mainly driven by higher volumes on account of improved asset utilization with higher capacities in the fourth quarter and year ended March 31, 2025.
Show source
The growth in the API business is mainly driven by higher volumes, on account of improved asset utilization with higher capacities.
- US formulation revenue increased by 13% year-on-year to Rs. 4,072 crores in Q4 FY25.
Show source
USA: For the quarter, the revenue from US formulation increased by 13% year-on-year to Rs. 4,072 crores.
- US revenue increased by 9% year-on-year to US$ 470 million on a constant currency basis in Q4 FY25, mainly driven by volume gains.
Show source
On a constant currency basis, US revenue increased by 9% year -on-year basis to US$ 470 million.
- US formulation revenue increased by 7% to Rs. 14,816 crores or US$ 1,752 million in FY25.
Show source
Revenue from US formulation increased by 7% to Rs. 14,816 crores or US$ 1,752 million.
- European formulation revenue was Rs. 2,147 crores in Q4 FY25, an increase of 17% year-on-year; in constant currency terms, Europe revenue was €236 million against €203 million of last year, driven by strong performance across all key geographies.
Show source
Europe: For the quarter, the European formulation clocked a revenue of Rs. 2,147 crores, an increase of 17% year -on-year.
- European formulation revenues grew by 17% to Rs. 8,356 crores or €921 million or US$ 988 million in FY25.
Show source
For the full year, the European formulation revenues grew by 17% and clocked a revenue of Rs. 8,356 crores or €921 million or US$ 988 million.
- Growth Market revenue declined 8% year-on-year and 10% quarter-on-quarter in Q4 FY25, to US$ 91 million, mainly on account of moderated performance in a few key markets.
Show source
Growth Market: For the quarter, Growth Market revenue stood at a year-on-year decline of 8% and quarter-on-quarter decline of 10%.
- ARV business increased by 29% year-on-year to Rs. 308 crores or US$ 36 million in Q4 FY25.
Show source
ARV business: For the quarter, ARV business increased by 29% year-on-year to Rs. 308 crores or US$ 36 million.
- ARV business increased by 19% to Rs. 1,037 crores or US$ 123 million in FY25, mainly due to continued momentum of additional opportunities.
Show source
For the year, ARV business clocked increased by 19% to Rs. 1,037 crores or US$ 123 million, mainly due to continued momentum of additional opportunities.
- Specialty and Injectable revenue increased by 25% year-on-year to US$ 178 million in Q4 FY25.
Show source
Specialty and Injectable update: For the quarter, revenue increased by 25% year-on-year to US$ 178 million.
- Specialty and Injectable global business increased by 4% to US$ 561 million in FY25, mainly due to volume gain partly offset by some pricing pressures.
Show source
For the year, Specialty and Injectable global business increased by 4% to US$ 561 million, mainly due to volume gain partly offset by some pricing pressures.
- Gross margin in Q4 FY25 was 59.1%, up about 65 basis points quarter-on-quarter, supported by favourable product mix and benign raw material prices, albeit constrained by other one-offs of over Rs. 105 crores plus.
Show source
Gross margin for the quarter was at 59.1%.
- R&D expenditure was Rs. 423 crores, 5% of revenue, in Q4 FY25, mainly towards clinical trial expenses for multiple projects.
Show source
R&D expenditures stood at Rs. 423 crores for the quarter, which is 5% of the revenue.
- R&D expenditure was Rs. 1,622 crores, 5.1% of revenue, in FY25, mainly towards clinical trial expenses for multiple projects.
Show source
For the year, R&D expenditure stood at Rs. 1,622 crores which is 5.1% of the revenue.
- European revenue is around €225, after consistently exceeding €200 million quarter-on-quarter.
Show source
But now that is no longer a challenge because we are already up towards €225 in terms of revenue.
- Unit 15 at Vizag is producing considerable volume output.
Show source
So, there is a very considerable volume output happening from our Unit 15.
- Other expenses during the year were Rs. 1,995 crores, against Rs. 1,805 crores, with the increase mainly attributable to translation impact rather than remediation charges in Q3 and Q4.
Show source
S. Subramanian: Tarang, the total other expenses during the year was Rs. 1,995 crores against Rs. 1,805 crores.
- The company had a one-off impact of Rs. 105 plus crores during the quarter, approximately split equally between cost of goods and other expenses.
Show source
S. Subramanian: See, we said there is a one-off impact of Rs. 105 plus crores during the quarter.
- Europe business generated US$ 987mn for the current year, and management expects it to scale past the billion-dollar mark next year.
Show source
As Subbu mentioned, it was US$ 987mn for the current year.
- Revenue base is around Rs. 32,000 crore; growth of 8 or 9% represents around Rs. 2,500 to Rs. 3,000 crores.
Show source
And when we say Rs. 32,000 grew by 8 or 9%, we are talking about a growth of around Rs. 2,500 to Rs. 3,000 crores.
- The company has reduced Malta batch turnaround time through innovative measures, enabling time-to-market opportunities and avoiding working capital being locked.
Show source
But through innovative measures, we are able to turn it around much faster.
- Gross margin in Q4 FY25 was 59.1%, up about 65 basis points quarter-on-quarter, supported by favourable product mix and benign raw material prices, albeit constrained by other one-offs of over Rs. 105 crores plus. Replaced by a later filing.
Money and capital
- Cash flows improved significantly on the backdrop of an improved working capital position, leading to a net cash surplus of US$ 42 million versus net debt of US$ 84 million as on December 31, 2024; its net cash position after investment stood at US$ 42 million, compared with a net debt position of US$ 84 million.
Show source
As a result, net cash position after investment stood at US$ 42 million from a net debt position of US$ 84 million.
- Improved profitability coupled with an improved working capital position generated net cash flow of US$ 130 million for Aurobindo Pharma Limited during Q4 FY25.
Show source
4 Aurobindo Pharma Limited 27 May 2025 Improved profitability coupled with improved working capital position, the business generated a net cash flow of US$ 130 million during the quarter.
- Average finance cost was 5.5% in the fourth quarter and year ended March 31, 2025.
Show source
The average finance cost of Rs. 5.5%.
- Net cash position after investment stood at US$ 42 million, compared with a net debt position of US$ 84 million. Replaced by a later filing.
What it expects ahead
What management expects
- The company does not expect a major impact from the tariff announcement likely in July ‘25, but says it needs to wait for the announcement.
Show source
But having said that, I want to make it clear that we need to wait for the impact on account of the tariff announcement, which is likely to happen in the month of July ‘25, even though we don't feel there will be a major impact, etc. Nevertheless, we should wait for the announcements.
- The company expects 10 products to begin contributing from China during the financial year, with two products already supplying.
Show source
Two products so far, but we expect 10 products to kick in during the financial year.
- The company expects close to 8-9% growth in Europe in the new fiscal, compared with generic growth in Europe of flat to low single digit or a maximum of 4 to 5%.
Show source
And I'm confident in this new fiscal as well, we'll be doing close to 8-9% growth, contributed by several factors, which I have already listed a couple of times.
- The company expects its biosimilar business to generate US$ 250 to around US$ 400 million in revenues by 2030 -31, depending on its portfolio and regulatory decisions in the US and other regulated markets.
Show source
Having said that, with the portfolio that we are having, especially with the four products that are now approved, followed by the Denosumab, Omalizumab, and the Bevacizumab, which are likely to get approved in the next 4-6 quarters, I expect by 2030 -31, the business would be anywhere between US$ 250 to around US$ 400 million in revenues.
- China OSD plant is expected to contribute revenues in FY26.
Show source
This plant is expected to contribute revenues in FY26.
- The company endeavours to achieve high single-digit growth excluding transient product through FY26.
Show source
It is our endeavour to achieve a high single-digit growth excluding transient product through FY26.
Show 4 more statements
What management expects
- The company internally aims to maintain its present EBITDA margins for FY26.
Show source
For FY26, we internally aim to maintain our present EBITDA margins.
- China unit, which had been incurring losses, is expected to break even or be nominally positive in the coming year. Aurobindo Pharma Limited's China plant has already incurred some losses and is expected to become break-even or slightly positive in the coming year.
Show source
In the China plant, already it has incurred some losses, and that will become break-even or slightly positive in the coming year.
- The company believes new product launches, the full-year impact of last year's launches and performance-improvement opportunities will help maintain profitability.
Show source
There are multiple opportunities which we are working on to improve the performance, coupled with the growth plans, which Murali has rightly explained by launching new products, the full year impact of the last year launches, etc., which will help to maintain the profitability.
- China plant has already incurred some losses and is expected to become break-even or slightly positive in the coming year. Replaced by a later filing.
What it is building and selling
Projects and capacity
- Net capital was US$ 90 million in Q4 FY25 and around US$ 322 million in FY25, including capacity enhancement projects, new plant expansions and others.
Show source
Net capital for the quarter is US$ 90 million and that for the year is around US$ 322 million, which includes capacity enhancement projects, new plant expansions and others.
- The company has expanded its formulation manufacturing capacity and currently has capacity of 60 billion unit plus.
Show source
We have expanded our Formulation manufacturing capacity further, and at present are having a capacity of 60 billion unit plus.
- The company substantially increased capacities at Unit 15 at Vizag for oral solids through strong investments.
Show source
This is not only by way of Vizag injectable plant, but also our Unit 15 at Vizag for the oral solids; the capacities have been substantially upped thanks to the management on strong investments.
- The company commercialized its China plant, with an annual OSD capacity of around 2 billion units that is expandable further over the near to medium term; the plant is expected to contribute to revenues in FY26.
Show source
We have commercialized our China OSD plant with 2 billion units manufacturing capacity during the year.
- China OSD plant capacity will be expanded further over the medium term.
Show source
The capacities will be expanded further over medium term.
- Vizag injectable facility is already approved, and supplies will start from Vizag.
Show source
Meaning, it is already approved and supplies will start from Vizag.
Show 3 more statements
Projects and capacity
- Production at Aurobindo Pharma Limited's Penicillin-G facility will resume promptly upon receiving the necessary approvals. Replaced by a later filing.
Show source
The production will resume promptly upon receiving the necessary approvals to avoid any undue risks.
- Proposed new capacity enhancements in existing facilities are expected to drive growth alongside its high capacities. Replaced by a later filing.
Show source
These high capacities along with the proposed new capacity enhancement s in the existing, are expected to drive the growth.
Demand and pricing
- Large product portfolio basket helped it optimally maintain price stability in the US in Q4 FY25.
Show source
Our large product portfolio basket helped us optimally maintain price stability.
Risks, rules and outside factors
Risks and disputes
- A preliminary assessment of the fire incident at Aurobindo Pharma Limited's Penicillin-G facility at Kakinada indicates an impact of around Rs. 4 crores.
Show source
Other update/Penicillin-G related issues: A preliminary assessment of the fire incident at Penicillin-G facility at Kakinada indicates an impact of around Rs. 4 crores.
- The company temporarily halted operations at its Penicillin-G facility after the fire incident; before the halt, it had achieved encouraging yields consistently in March.
Show source
In the interim, due to the incident, we had temporarily halted the plant operation s. Before temporarily halting the operations, we have achieved encouraging yields consistently in the month of March.
Rules and policy
- Tariff announcements are expected in July ‘25.
Show source
The tariff announcements are expected in July ‘25.
- The company submitted the renewal application for Consent to Operate for its Penicillin-G facility.
Show source
Further, as part of the commitment to regulatory compliance, we have submitted the renewal application for Consent to Operate.
- Minimum import prices are being considered on certain critical raw materials, and Aurobindo Pharma Limited has made a representation to the industry associations.
Show source
We also understand from the industry sources, that the minimum import prices are being considered on certain critical raw materials, and accordingly, we have made representation to the industry associations.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Damayanti Kerai: Hi, good morning. My first question is on Revlimid. So, I understand moving from 3Q to 4Q, you have booked sizably large sales from Revlimid. But my question is whether this 4th Quarter number, it reflects what you originally planned , or have you held back some supplies due to some price renegotiation which we are seeing in the market due to entry of additional competition in the market for Revlimid?
Answer, yugandhar puvvala
Yugandhar Puvvala: Damayanti, normally, we don't comment on Revlimid sales or units or value. But yeah, like in fact, we have done whatever we planned to do. And we are only left with balance for the next year. But beyond that, I think I won't be in a position to comment in terms of the numbers.
Question
Damayanti Kerai: Sure, but nothing has spilled over from 4Q to next fiscal, if you can just indicate that.
Answer, yugandhar puvvala
Yugandhar Puvvala: We haven't. In fact, like nothing has spilled from Q4 to the next year. It is just as planned. We have done it. So, whatever limited quantity will be there for FY26, that is what we will do. But there's nothing, no spillovers from FY25 to FY26.
Question
Damayanti Kerai: Sure. And in your margin expectation for FY26, which you mentioned to be at similar level, are you including significant pickup happening from, say, China plant or some of the plants in the US? 6 Aurobindo Pharma Limited 27 May 2025 S. Subramanian: See, US plant, Swami will talk about it, and which we have already mentioned it in the original remarks.
Answer, s subramanian
In the China plant, already it has incurred some losses, and that will become break-even or slightly positive in the coming year.
Question
Damayanti Kerai: And China is supplying to all the markets, right? Local market as well as Europe and US, or…?
Answer, s subramanian
S. Subramanian: No, not US. They are they will be supplying to China during the year, as well as Europe. Europe, they can start immediately. But China, they will be able to do it after some time, maybe Q2.
Answer, swami iyer
Swami Iyer: Subbu, I can contribute here for Europe, from China plant, the supplies have already started.
Question
Damayanti Kerai: Okay, that's helpful. And in the US plant, Dayton is supplying normally, but Raleigh facility is something where you believe pickup will happen like in some time. Right now, I think there is pending issues, right?
Answer, swami iyer
Swami Iyer: I'm not sure I heard Damayanti fully, but Dayton plant is going to commence the manufacturing on a commercial basis. They have manufacturing of course, and then we expect commercialization in the Q2 of the current fiscal. And the other facility that you talked about, Damayanti, I am not sure what exactly you are saying.
Question
Damayanti Kerai: What is the status?
Answer, swami iyer
Swami Iyer: So, the Raleigh facility, we had an FDA inspection, and some issues were raised. We are addressing it proactively. The Raleigh plant does not have much contribution in terms of revenue currently, and we do not have any major product launches that is planned in the short term. So, we believe that this is not going to impact our numbers in a meaningful way.
Question
Tushar Manudhane: Thank you, sir. Just on the margin front, while the start of P en-G plant, probably resumption of normalization in Eugia-3. On the positive side, probably offsetting the Revlimid impact. Is there any other factor to be considered for margin uptick or downtick for FY26?
Answer, s subramanian
S. Subramanian: See, some of the new units, like China, which I explained, they were incurring some losses, which is expected to be break-even or a very nominal positive in the coming year. Like that, every unit, whatever has happened, we are able to improve upon the performance. Across all the businesses we have been looking at it.
Question
Tushar Manudhane: Can you quantify how much losses are China plant for FY25?
Answer, s subramanian
S. Subramanian: The China plant last year was the first year. We have incurred a loss of around Rs. 35 crore plus. There are multiple opportunities which we are working on to improve the performance, coupled with the growth plans, which Murali has rightly explained by launching new products, the full year impact of the last year launches, etc., which will help to maintain the profitability. That's what we believe. But having said that, I want to make it clear that we need to wait for the impact on account of the tariff announcement, which is likely to happen in the month of July ‘25, even though we don't feel there will be a major impact, etc. Nevertheless, we should wait for the announcements.
Question
Neha Manpuria: Yeah, thanks for taking my question. First question on the US business. I know you're not giving the breakup of the US anymore, but just wanted to understand improvement in both the base business in the injectable as well as the oral solid. Is it fair to assume that the injectable business has gone back to pre-disruption levels Unit 4 [Eugia Unit- 3] disruption levels in this quarter?
Answer, yugandhar puvvala
Yugandhar Puvvala: Neha, I think last year we have taken whatever supply-related disruption issues and it got offset by some other opportunities. But I think from Q1 of next financial year 8 Aurobindo Pharma Limited 27 May 2025 i.e. FY26 Q1 onwards, we should be back to normal. But last year has been a tough year because of Eugia-3 remediation issues and supply disruptions. But I think from Q1 onwards, we should be back to where we were in the past.
Question
Neha Manpuria: And Yugandhar, how should I think about growth for the injectables? I mean, you know, given that Unit 4 [Eugia-3] hasn't been cleared as yet? How do we see growth in the Eugia business, as Revlimid also goes away? So just some colour there.
Answer, yugandhar puvvala
Yugandhar Puvvala: Neha, like FY26 is going to be muted in terms of growth per se, because obviously you said it right, Eugia-3 is yet to be cleared and there's no super star product which is going to come in FY26. But we expect FY26 to be in the similar levels as FY25, whether it is including or excluding Revlimid. But FY27 should be a good year. That is what we believe, that FY26, we will be in a position to clear all the issues with FDA. And FY27, we have significant launches and settlement-based launches that are planned. So, FY27 should be a great year. But FY26 will be muted in terms of growth.
Show 18 more questions
Question
Neha Manpuria: Got it. My second question is on the PLI capacity. Subbu, post the fire, by when do we expect production to normalize here? Would it be fair to assume that the PLI capacity we were expecting to be profitable and ramp up . Is that still on track or could there be some delays on it based on when we get back to operation on the PLI capacity?
Answer, s subramanian
S. Subramanian: So, Neha, to put it clearly, and if we are to make a profit as contemplated, we need to run the plant full capacity. We don't want to run the plant half of the capacity pending the approval, because it's a big plant. If some minor accident happens or etc., it will have a great impact which we don't want to take that risk. And second is, today on TV, I have seen that the COVID is once again coming back with all these things. Probably, government may start looking into that, giving the approval fast, that is there. And third, I understand from the industry, government is also working on the minimum import prices. If that happens, then it will be a good and ensure that we are not incurring losses and we will be able to achieve the profits as contemplated or planned earlier.
Question
Surya Patra: Yeah, thanks for the opportunity, sir, and good set of numbers. Congrats for the good set of numbers, basically. My first point is, in the opening remarks, you mentioned that the growth is likely to be sustained in FY26. But you highlighted about the growth obviously would be led by the Europe and emerging market s, but kind of remained silent about the other bigger markets like US and all. So, knowing the fact that US contribute s almost like 45% 9 Aurobindo Pharma Limited 27 May 2025 of the total. So, is there a kind of a risk that we have to the overall growth guidance? Or if you can give clarity more on the US business?
Answer, s subramanian
S. Subramanian: Surya, I told in the opening remarks, we will be able to achieve high single digit revenue growth, excluding the transient product. And we will be able to give better clarity post tariff announcements. But as on date, the existing business, we are trying to grow it with a high single digit growth.
Question
Surya Patra: Okay, okay, fine. Regards the European business, it looked like that it has surpassed your earlier guidance of €900 odd billion. And now, optically, there are things which should contribute incrementally to the growth. And you have also mentioned about the possibility or what are the factors of growth here. I just wanted to have a sense that , regards the kind of facilities that would be contributing towards the growth. So, obviously, we have been saying that the China plant which has commissioned, that will facilitate the growth in Europe. The Vizag facility is also likely to see the injectable growth in Europe. So, on that specific front, sir, supply chain for Europe, if you c
Answer, v muralidharan
V. Muralidharan: Yeah, thank you. Thank you for this question. On our current revenue achievement, as you have noted, quarter-on-quarter, consistently, we are crossing the €200 million mark. But now that is no longer a challenge because we are already up towards €225 in terms of revenue. And how we are able to accomplish this, is again, how the supply chain efficiency is going to further contribute to this. This is not only by way of Vizag injectable plant, but also our Unit 15 at Vizag for the oral solids; the capacities have been substantially upped thanks to the management on strong investments. So, there is a very considerable volume output happening from our Unit 15.
Answer, v muralidharan
And China supplies have just started. Two products so far, but we expect 10 products to kick in during the financial year. And the injectable facility also will be up and running. Meaning, it is already approved and supplies will start from Vizag. Additionally, I would like to touch upon the turnaround time of the batches at Malta, because we have a substantial volume and there the waiting time was significant. But through innovative measures, we are able to turn it around much faster. So, that allows the time to market opportunities being availed and working capital not being locked, which benefits us there.
Answer, v muralidharan
So, a combination of all this means enhanced capacities, turnaround time at Malta, and also more and more tech transfers are happening that will offer better gross margin upside for us. So, I'm just addressing your queries through this. Anything else to be touched upon, do let me know. Thank you.
Question
One, sir, if I look at your fixed cost base excluding R&D for FY25 versus FY24, there's been a quantum leap. And we're aware that it's because of plethora of reasons, Eugia remediation, Pen-G, Vizag, China, so on and so forth. I mean, just to get a sense, how much would that quantum be for FY25, these one-offs, because of regulatory reasons because of state considerations or because of just amplifying capacity, which is not contributing to revenue.
Answer, s subramanian
S. Subramanian: Tarang, the total other expenses during the year was Rs. 1,995 crores against Rs. 1,805 crores. The other expenses have not grown significantly. One of the reasons is the translation impact is taking place. Otherwise, the fixed expenses remained the same in India, Eugia, USA,etc . Because Euro earlier, we used to translate at a lower price , I mean, lower rate, now we translated at a higher rate. So, you cannot exactly say there is a significant impact. You look at the Q3, Q4 alone, where there is not much of remediation charges , it is mainly on account of the translation impact.
Question
Tarang Agarwal: Okay. So, I mean, the one -offs like the Rs. 100 crore that you spoke of in Q4 , and in Q1 and Q2, we are aware that P en-G and remediation was resulting in a significant expansion in cost space. So, I was just trying to get a sense on what that number is. Would that be to the tune of Rs. 400-500 crores for FY25 or would it be materially low?
Answer, s subramanian
S. Subramanian: See, we said there is a one-off impact of Rs. 105 plus crores during the quarter. You take 50-50 between the cost of goods and other expenses, approximately.
Question
Tarang Agarwal: I mean, OTC used to be about US$ 100 million for you. So, how much did was OTC for you in FY26? And what is your perspective on the oral solids business for FY26?
Answer, v muralidharan
V. Muralidharan: Yeah, typically, we do not talk about the numbers for OTC, that I leave it to Subbu. But in terms of growth, OTC has done well in the last two quarters, this quarter has been good, it continues to be good and it continues to grow. So, we are looking forward to better growth in OTC. With regard to OSD, we believe that we are confident in our outlook for improved growth in the current fiscal, which is FY26. We have planned a number of new launches . And our team continues to assess opportunities with a view to drive medium to long -term growth and value creation with a more diversified portfolio of growth drivers , primarily. So, this is what we are looking at, and we are optimistic in short.
Question
Amey Chalke: Taking the biosimilar question from Tarang ahead. So, is it possible to give some colour, because we have said in the presentation that we would be launching biosimilars in Europe next year. When should we expect meaningful contribution to come in , considering three to four products are already filed in Europe? Dr. Satakarni Makkapati: Amey, this is Satakarni.
Answer, satakarni makkapati
So, in the biosimilar space, as you know that we received two approvals from the European Medicines Agency in the last quarter. And we had one approval of Bevqolva in Q3 of the last fiscal. We also received a positive opinion for Dazublys, which is our version of Trastuzumab biosimilar, I think, last month and we are expecting the approval from the European Commission in July. So, we plan to start our supplies from the 2nd Quarter, as I mentioned in the last earnings call, from the 2nd Quarter of this fiscal. Once we iron out our supply chain and stabilize our manufacturing and supplies, I expect the meaningful contributions from the biosimilars business to flow in from the next fiscal year. We expect it to be a double-digit revenue starting the next fiscal.
Answer, swami iyer
Swami Iyer: So, this is not in the near term. I think we are progressing better than what we anticipated in terms of filings. We believe that these products would come in to the medium term, not necessarily the short term.
Answer, swami iyer
Swami Iyer: So, injectable product, I will leave it to Yugandhar to talk about. As far as the short-term drivers are concerned, we expect newer launches from the oral solids and volume increases in certain products that we have launched recently. And also, some other new launches that we did in the last 1-2 quarters.
Question
Bino: Hi, good morning, good evening. First question to Murali, you know, just probably a little bit more on Europe, you said the FY26 will see an improved growth because of some LOE products, etc. So, one, would you be able to name some of these LOE products? And two, assume we have a very good growth in FY26, how should we look at growth in this market, being a mature market ahead, FY27 to date, etc? Will it come back to the normal market growth rate of single digit or do you see a pretty long runway? 12 Aurobindo Pharma Limited 27 May 2025 V. Muralidharan: Thank you, Bino, for this question.
Answer, v muralidharan
Let me take up the growth first and then the LOE products. So, in terms of growth, the generic growth in Europe is rather flat or low single digit or maximum 4 to 5%. But we have been consistently clocking a high single digit growth. And I'm confident in this new fiscal as well, we'll be doing close to 8-9% growth, contributed by several factors, which I have already listed a couple of times. And, you know, internally, we had kept a billion -dollar mark for this year as our mission, and we almost reached that. As Subbu mentioned, it was US$ 987mn for the current year. So, obviously, next year we'll be scaling past the billion mark in style.
Answer, v muralidharan
Coming to the LOE products, there are about six products. I'm not sure whether I can name these at this moment, but these will be launched during the year, market -by-market. In some cases, we are going on a risk-based approach based on the legal opinion we have got, but we are confident we'll be able to successfully launch and clock the annualized revenues in the next fiscal. Thank you. Bino: Understood. Second question, a follow-up to Yugandhar. You mentioned about a few interesting launches, including settlements in the US in FY27.
Answer, yugandhar puvvala
Yugandhar Puvvala: Yeah, it is public information. So, we have most of the oncology oral solids which are going to come, which is related to Pomalidomide, Nintedanib, Sugammadex. So, there are multiple. In fact, we have tentative approvals. We expect final approval to happen just before the launch, but there are multiple settlements which will kick in end of FY26 and into FY27. So, I think beyond that, I cannot read the entire list, but yes, we have interesting launches lined up for FY27. Bino: Got it.
Answer, yugandhar puvvala
Yugandhar Puvvala: No. Bino: Okay. And one last, Subbu sir, the tax rate for the year was high compared to earlier years. What should we look at for FY26 at a consolidated level?
Answer, s subramanian
S. Subramanian: I think the tax rate, the general tax rate for us is around 25% . But being very conservative, we don't take the deferred tax credit for all the loss -making units. Once they start becoming break -even, et cetera, I will get the tax rates done. So, you can take approximately 28 to 30% is the tax rate. Probably you'll get a better idea going forward in the coming quarters. Bino: Thank you. Thank you very much.
Question
Andre: So, my question is rather broad, but in the opening remarks, Mr. Sant hanam said that he was quite satisfied with the good results which you have in the last year. Now, if I were to look at it from an outside perspective, with the exception of the European business, the general growth trajectory in last year has been somewhere in the neighbourhood of 10%, 13 Aurobindo Pharma Limited 27 May 2025 whether you look at revenues or profit, etc. I'm making a slightly broad statement. Now, what is it that makes you say that these results are good? I want to understand your own evaluation and your own expectations of the business. Were there conditions in the business that were rather difficul
Answer, s subramanian
S. Subramanian: See, this year, if you really see the Q4, year-on-year growth, we have achieved around 10%. So, we are saying, excluding the transient product, we'll be achieving around high single -digit growth. That means the base business is growing consistently, Plus anything, the transient product will contribute, which has been mentioned earlier, that will get added to that. And second, please do not expect all businesses have to continuously perform every quarter. That is the reason what we have done is, you see, there will be some pressure for any, some business in some quarter, etc. So, we are making the results, everything on a market basis,. That is the reason you have to look at it. If we get into every business, this business is growing, not growing, etc., it's very difficult.
Answer, s subramanian
And second, with such a base [revenue] of around Rs. 32,000 crore, some quarters there may be a drop, some quarters there may be a high. But overall, you have to look at the year as a whole, whether we are doing it or not doing it like that. It's not a small business where it can grow by 50%, 40%, 30% like that. It's a very big business. And when we say Rs. 32,000 grew by 8 or 9%, we are talking about a growth of around Rs. 2,500 to Rs. 3,000 crores. Andre: Okay. So, if I would understand you correctly, what you're saying is that for a business with a large base, there are different components, which will at any point of time move in different directions .
Answer, s subramanian
Some will grow in … S. Subramanian : Different directions, but our job is to ensure that overall, everything put together on a consolidated basis, we have to grow. Andre: So, therefore, a growth of 10% overall is good by your internal measures.
Question
Sir, one is, if you can explain importance of Eugia Unit-5 versus Unit-3, I mean, Unit-3 has been discussed a lot, but if you can give some more clarity with regards to how Unit-5 versus Unit-3.
Answer, yugandhar puvvala
Yugandhar Puvvala: Yeah, Unit 5 Jigar, we have already four lines which are installed, and we are actually almost adding four more lines related to BFS, PFS, cartridge, and one more aseptic line. So, it will be almost eight significant lines with capabilities of aseptic, terminally sterilized , cartridge products and BFS products and bag products. So, we expect Vizag to be a future plant, not only as a de -risking for Eugia-3, but also contributing significantly starting F Y27. So, we have plans of filing roughly around 10 products for US and around 15 products for Europe. And obviously, all these products will be extended to the other geographies. So, F Y26 will be the significant filing year , with FY27 contributing decent enough revenues for this plant. So, if you need to know anything else, most welcome, you can ask.
Question
Jigar Walia: This is helpful. And Unit-3 would be also having eight lines or would it be …?
Answer, yugandhar puvvala
Yugandhar Puvvala: No, that Unit-3 has actually 17 lines. Okay. So, we don't want to create such a massive plant again, but we wanted to limit any future plan ts to be in the range of maximum 10 lines. So, we have expansion possibilities within the Vizag plant, but only thing is, at this point of time, we want to restrict ourselves to around eight lines.
Question
Jigar Walia: Makes sense. Thank you. The other question is, you partially mentioned in terms of the cumulative investments on Biosimilar, etc. But overall, as a company, we made investments in Pen-G, Biosimilar and CDMO, and these are probably not contributing positively to the earnings as of now. If you can just give a cumulative number in terms of investments and maybe how much is a cumulative type of impact on the P&L now, and as it normalizes, so one can understand the data going ahead. Santhanam Subramanian: I can give you a very broad, rough estimate. We have invested around Rs. 2,700 crores in Pen-G. It has the potential to take the EBITDA more than Rs. 1,000 crores. It has the potent
Answer, satakarni makkapati
The plant would be commissioned in Q2 of the next fiscal [FY27], and we expect the validation batches to complete by Q4 [FY27], which means we will see the revenues coming in from the following fiscal [FY28]. It takes time to build these plants, two and a half to three years. So, we are very much on track with commissioning the facilities and ensuring that it becomes into the commercial supply chain soon in the next 4-6 quarters’ time.
Question
Jigar Walia: Got it. And over, I mean, roughly over what, 3-4 years, should we see that these would earn company level EBITDA margins or could it be sooner? 15 Aurobindo Pharma Limited 27 May 2025 Dr. Satakarni Makkapati: For the CMO, it would be about 3-5 years’ time frame, because it depends on the sponsor or the client and what capacities will they actually utilize, which we think is fair bit of capacities right now.
Answer, satakarni makkapati
And also, it depends on, once you complete your validation batches, how long would it take for the regulatory approvals to come in. So, anywhere between 3-5 years’ time frame, 3 the best case and 5 the worst case, we see normalcy sitting in.
Question
Jigar Walia: Great. Last, if I can squeeze in with the free cash flows improving post-CapEx commitments, is there any possibility for buybacks?
Answer, s subramanian
S. Subramanian: That's a good question. The last buyback was closed on August 31st 2024. So, you cannot do a buyback before August of this year. So, we have enough time to think about it and our cash flows are pretty strong. Maybe bo ard can consider either buyback or dividend. But the probability is good, actually, with the cash flows strengthening.
Question
Shyam Srinivasan: Good morning. Thank you for taking my question. Just the first one on the on the Pen-G plant. I just want to understand a little bit about the fire accident and the subsequent 20-25 day… I think you also put a press release yesterday saying you are waiting some approval from the Andhra board. So, just can you give some clarity around what went wrong and what are the mitigation efforts and when does this restart? That's question one. Also want to know in terms of production, how are we thinking, again Pen-G? What is the monthly or the annual trajectory we would likely go back to? And Subbu sir, you also mentioned about prices for Pen-G, if they are favourable, we'll do certa
Answer, s subramanian
S. Subramanian: So, the first question is fire accident. This fire accident happened in the coal yard near the conveyor belt. This has happened because of the self-ignition of the coal heap. What I understand from the technical people, the temperature on the surface vis-à-vis temperature inside the coal heap was very high, and that led to self-ignition of the coal. And this is very common if you really see in the cement industries, etc. But unfortunately, it was near the conveyor belt, which has impacted the conveyor belt, and that has been rectified. In the meantime, we also applied for the renewal as one year was over in April. So, we have subjected ourselves to the inspection.
Answer, s subramanian
And in the meantime, this accident has happened and hence it could not be proceeded with. Now, we'll take it up with the PCB (Pollution Control Board). We cannot give a time frame, but certainly, everybody will look into this project positively. And apart from that with the new COVID news, we need to push the government very fast, which we are likely to do going forward. 16 Aurobindo Pharma Limited 27 May 2025 And third, in terms of the pricing, etc. 6-APA pricing, etc., I mean, if it is low, it's good. We can also take advantage of that, so that we can make more money than what we can anticipate by doing it ourselves, unless the minimum import price comes, etc. It's always better to take advantage of any opportunities coming in terms of reduced price. That's the way any company will do that.
Question
Shyam Srinivasan: Thank you, Subbu sir. Helpful. This minimum input price, you mentioned this few times. Sorry, I have not understood what the proposal is. Is it to help domestic industry? Sorry, can you explain what could be the contours of it?
Answer, s subramanian
S. Subramanian: I think what I understood from the industry sources is, government is contemplating of putting the minimum input prices of few products, etc. So, we have also represented our product. Once we come to know from the government anything officially, we will certainly let you know .
Question
Shyam Srinivasan: All PLI products. Understood. Okay, I got it.
Answer, s subramanian
S. Subramanian: Yeah. I mean, this is, we came to know from the industry sources. I want to make it abundantly clear.
Question
Is it a $500 million business, a billion-dollar business? Where does it get to in terms of the investments that we made and the capabilities that we have in this business? Dr. Satakarni Makkapati: So, in one of my earlier answers to one of the earnings call questions, I explained that I would hate to put numbers to it because we are looking at extremely complex and dynamic environments, both in Europe as well as the US when it comes to biosimilar business and its disruption.
Answer, satakarni makkapati
Having said that, with the portfolio that we are having, especially with the four products that are now approved, followed by the Denosumab, Omalizumab, and the Bevacizumab, which are likely to get approved in the next 4-6 quarters, I expect by 2030 -31, the business would be anywhere between US$ 250 to around US$ 400 million in revenues. It depends on various factors . So, it is very subjective, and you cannot pinpoint to a certain number, but expect to be a significant size provided certain regulatory decisions go our way in the US and other regulated markets.
Questions about this call
- When was the Aurobindo Pharma Q4 FY25 earnings call transcript filed?
- Aurobindo Pharma filed the transcript with the exchange on 2 Jun 2025. This page is built from that transcript.
- What does this page list?
- 68 statements from the transcript across 7 topics, 53 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 28 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.